Comparisons of the binding of [14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry

Chemico-Biological Interactions

Volumn 106, Issue 2, 1997, Pages 149-160

  White, Ian N H ^a   Martin, Elizabeth A ^a   Mauthe, Robert J ^b   Vogel, John S ^b   Turteltaub, Kenneth W ^b   Smith, Lewis L ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

32P postlabelling; Accelerator mass spectrometry; DNA binding; Tamoxifen; Toremifene

Indexed keywords

TAMOXIFEN; TOREMIFENE; DNA; GLOBIN;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; DRUG DNA INTERACTION; FEMALE; MASS SPECTROMETRY; NONHUMAN; RAT; ANIMAL; BIOTRANSFORMATION; COMPARATIVE STUDY; DNA ADDUCT; DNA DAMAGE; FISCHER 344 RAT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER; LIVER MICROSOME; METABOLISM; MOUSE; MOUSE STRAIN; PROTEIN BINDING; THIN LAYER CHROMATOGRAPHY;

ANIMALS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; DNA; DNA ADDUCTS; DNA DAMAGE; FEMALE; GLOBINS; HUMANS; LIVER; MASS SPECTROMETRY; MICE; MICE, INBRED STRAINS; MICROSOMES, LIVER; PROTEIN BINDING; RATS; RATS, INBRED F344; TAMOXIFEN; TOREMIFENE;

EID: 0030613674     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(97)00063-X     Document Type: Article

References (28)

1. Powles T.J., Jones A.L., Ashley S.E., O'Brien M.E.R., Tidy V.A., Treleavan J., Cosgrove D., Nash A.G., Sacks N., Baum M., McKinna J.A., Davey J.B. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res. Treat. 31:1994;73-82.
2. NSABP Contributors, Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86:1994;527-537.
3. Hard G.C., Iatropoulos M.J., Jordan K., Radi L., Kaltenberg O.P., Imondi A.R., Williams G.M. Major differences in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Cr1:CD(BR) rats. Cancer Res. 53:1993;4534-4541.
4. Greaves P., Goonetilleke R., Nunn G., Topham J., Orton T. Two-year carcinogenicity study of tamoxifen in Alderly Park Wistar-derived rats. Cancer Res. 53:1993;3919-3924.
5. M.J. Tucker, H.K. Adams, J.S. Patterson, Tamoxifen, in: D.R. Laurence, A.E.M. McLean, M. Weatherall (Eds.), Safety Testing of New Drugs, Academic Press, New York, 1984, pp. 125-161.
6. White I.N.H., De Matteis F., Davies A., Smith L.L., Crofton Sleigh C., Venitt S., Hewer A., Phillips D.H., Crofton Sleigh C. Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats, DBA/2 and C57Bl/6 mice and in human MCL-5 cells. Carcinogenesis. 13:1992;2197-2203.
7. Mani C., Kupfer D. Cytochrome P450 mediated action and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of the flavin-containing monooxygenases in tamoxifen activation. Cancer Res. 51:1991;6052-6058.
8. 14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem. Pharmacol. 49:1995;1035-1042.
9. Moorthy B., Sriram P., Pathak D.N., Bodell W.J., Randerath K. Tamoxifen metabolic activation: Comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res. 56:1996;53-57.
10. Frantz C.E., Bangerter C., Fultz W., Mayer K.M., Vogel J.S., Turteltaub K.W. Dose-response studies of MeIQx in rat liver and liver DNA at low doses. Carcinogenesis. 16:1995;367-373.
11. Felton J.S., Turteltaub K.W. Accelerator mass spectrometry for measuring low-dose carcinogen binding to DNA. Environ. Health Perspect. 102:1994;450-452.
12. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
13. 32P-postlabelling in three rat stains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation. Carcinogenesis. 16:1995;1299-1304.
14. Pathak D.N., Bodell W.J. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis. 15:1994;529-532.
15. K.W. Turteltaub, J.S. Vogel, C.E. Frantz, F. Fultz, Studies on DNA adduction with heterocyclic amines by accelerator mass spectrometry: a new technique for tracing isotope-labelled DNA adduction, in: D.H. Phillips, M. Castegnaro, H. Bartsch (Eds.), Postlabeling Methods for Detection of DNA Adducts, IARC, Lyon, 1993, pp. 293-301.
16. Osborne M.R., Hewer A., Hardcastle I.R., Carmichael P.L., Phillips D.H. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res. 56:1996;66-71.
17. Tornqvist M., Mowrer J., Jensen S., Ehrenberg L. Modified Edman degredation applied to hemoglobin adducts by a modified Edman degredation method. Anal. Biochem. 154:1986;255-266.
18. Jones N.J., Parry J.M. The detection of DNA adducts, DNA base changes and chromosome damage for the assessment of exposure to genotoxic pollutants. Aquat. Toxicol. 22:1992;323-343.
19. Mani C., Pearce R., Parkinson A., Kupfer D. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis. 15:1994;2715-2720.
20. Phillips D.H., Carmichael P.L., Hewer A., Cole K.J., Hardcastle I.R., Poon G.K., Keough A., Strain A.J., Keogh A. Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: Comparisons between human, rat and mouse hepatocytes. Carcinogenesis. 17:1996;89-94.
21. Lim C.K., Yuan Z., Lamb J.H., White I.N.H., De Matteis F., Smith L.L. A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis. 15:1994;589-593.
22. Dehal S.S., Kupfer D. Evidence that the catechol 3,4-dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. Cancer Res. 56:1996;1283-1290.
23. Phillips D.H., Carmichael P.L., Hewer A., Cole K.J., Poon G.K. α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA binding activity in rat hepatocytes. Cancer Res. 54:1995;5518-5522.
24. Hemminki K., Widlak P., Hou S.M. DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis. 16:1995;1661-1664.
25. 32P-Postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis. 16:1995;1651-1654.
26. Carmichael P.L., Ugwumadu A.H.N., Neven P., Hewer A.J., Poon G.K., Phillips D.H. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res. 56:1996;1475-1479.
27. Pathak D.N., Pongracz K., Bodell W.J. Activation of 4-hydroxytamoxifen and the tamoxifen derivative metabolite E by uterine peroxidase to form DNA adducts: Comparison with DNA adducts formed in the uterus of Sprague-Dawley rats treated with tamoxifen. Carcinogenesis. 17:1996;1785-1790.
28. Hemminki K., Rajaniemi H., Lindahl B., Moberger B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res. 56:1996;4374-4377.